BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 8648690)

  • 1. Transcription of the Epstein-Barr virus nuclear antigen 1 (EBNA1) gene occurs before induction of the BCR2 (Cp) EBNA gene promoter during the initial stages of infection in B cells.
    Schlager S; Speck SH; Woisetschläger M
    J Virol; 1996 Jun; 70(6):3561-70. PubMed ID: 8648690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determining the role of the Epstein-Barr virus Cp EBNA2-dependent enhancer during the establishment of latency by using mutant and wild-type viruses recovered from cottontop marmoset lymphoblastoid cell lines.
    Yoo L; Speck SH
    J Virol; 2000 Dec; 74(23):11115-20. PubMed ID: 11070007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-cell lines immortalized with an Epstein-Barr virus mutant lacking the Cp EBNA2 enhancer are biased toward utilization of the oriP-proximal EBNA gene promoter Wp1.
    Yoo LI; Mooney M; Puglielli MT; Speck SH
    J Virol; 1997 Dec; 71(12):9134-42. PubMed ID: 9371570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of critical cis elements involved in mediating Epstein-Barr virus nuclear antigen 2-dependent activity of an enhancer located upstream of the viral BamHI C promoter.
    Jin XW; Speck SH
    J Virol; 1992 May; 66(5):2846-52. PubMed ID: 1313905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. oriP is essential for EBNA gene promoter activity in Epstein-Barr virus-immortalized lymphoblastoid cell lines.
    Puglielli MT; Woisetschlaeger M; Speck SH
    J Virol; 1996 Sep; 70(9):5758-68. PubMed ID: 8709191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.
    Lear AL; Rowe M; Kurilla MG; Lee S; Henderson S; Kieff E; Rickinson AB
    J Virol; 1992 Dec; 66(12):7461-8. PubMed ID: 1331531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral and cellular factors influence the activity of the Epstein-Barr virus BCR2 and BWR1 promoters in cells of different phenotype.
    Nilsson T; Sjöblom A; Masucci MG; Rymo L
    Virology; 1993 Apr; 193(2):774-85. PubMed ID: 8384755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual EBNA1 promoter usage by Epstein-Barr virus in human B-cell lines expressing unique intermediate cellular phenotypes.
    Taylor KA; Wetzel S; Lyles DS; Pollok BA
    J Virol; 1994 Oct; 68(10):6421-31. PubMed ID: 8083980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latency pattern of Epstein-Barr virus and methylation status in Epstein-Barr virus-associated hemophagocytic syndrome.
    Yoshioka M; Kikuta H; Ishiguro N; Endo R; Kobayashi K
    J Med Virol; 2003 Jul; 70(3):410-9. PubMed ID: 12767005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis.
    Kelly GL; Milner AE; Tierney RJ; Croom-Carter DS; Altmann M; Hammerschmidt W; Bell AI; Rickinson AB
    J Virol; 2005 Aug; 79(16):10709-17. PubMed ID: 16051863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Epstein-Barr virus BamHI C promoter is not essential for B cell immortalization in vitro, but it greatly enhances B cell growth transformation.
    Tierney RJ; Nagra J; Rowe M; Bell AI; Rickinson AB
    J Virol; 2015 Mar; 89(5):2483-93. PubMed ID: 25540367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role for the Epstein-Barr virus nuclear antigen 2 in viral promoter switching during initial stages of infection.
    Woisetschlaeger M; Jin XW; Yandava CN; Furmanski LA; Strominger JL; Speck SH
    Proc Natl Acad Sci U S A; 1991 May; 88(9):3942-6. PubMed ID: 1850841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state.
    Tierney RJ; Steven N; Young LS; Rickinson AB
    J Virol; 1994 Nov; 68(11):7374-85. PubMed ID: 7933121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deletion of Epstein-Barr virus regulatory sequences upstream of the EBNA gene promoter Wp1 is unfavorable for B-Cell immortalization.
    Yoo LI; Woloszynek J; Templeton S; Speck SH
    J Virol; 2002 Nov; 76(22):11763-9. PubMed ID: 12388739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of transcripts initiated from two viral promoters (Cp and Wp) in Epstein-Barr virus-infected nasopharyngeal carcinoma cells and biopsies.
    Chang Y; Sheen TS; Lu J; Huang YT; Chen JY; Yang CS; Tsai CH
    Lab Invest; 1998 Jun; 78(6):715-26. PubMed ID: 9645762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variable methylation of the Epstein-Barr virus Wp EBNA gene promoter in B-lymphoblastoid cell lines.
    Elliott J; Goodhew EB; Krug LT; Shakhnovsky N; Yoo L; Speck SH
    J Virol; 2004 Dec; 78(24):14062-5. PubMed ID: 15564516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constitutive activation of Epstein-Barr virus (EBV) nuclear antigen 1 gene transcription by IRF1 and IRF2 during restricted EBV latency.
    Schaefer BC; Paulson E; Strominger JL; Speck SH
    Mol Cell Biol; 1997 Feb; 17(2):873-86. PubMed ID: 9001242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Host cell and EBNA-2 regulation of Epstein-Barr virus latent-cycle promoter activity in B lymphocytes.
    Rooney CM; Brimmell M; Buschle M; Allan G; Farrell PJ; Kolman JL
    J Virol; 1992 Jan; 66(1):496-504. PubMed ID: 1309259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional interaction of nuclear factor y and sp1 is required for activation of the epstein-barr virus C promoter.
    Boreström C; Zetterberg H; Liff K; Rymo L
    J Virol; 2003 Jan; 77(2):821-9. PubMed ID: 12502798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unique Epstein-Barr virus (EBV) latent gene expression, EBNA promoter usage and EBNA promoter methylation status in chronic active EBV infection.
    Yoshioka M; Kikuta H; Ishiguro N; Ma X; Kobayashi K
    J Gen Virol; 2003 May; 84(Pt 5):1133-1140. PubMed ID: 12692278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.